RO 6864018

Drug Profile

RO 6864018

Alternative Names: RO-6864018

Latest Information Update: 19 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 03 Nov 2017 Roche completes a phase II trial in Hepatitis B (Treatment-experienced) in Hong Kong, South Korea, Malaysia, New Zealand, Singapore and Taiwan (NCT02391805)
  • 11 Nov 2016 Adverse events, pharmacodynamic and pharmacokinetics data from a phase I trial in Hepatitis B presented at The Liver Meeting 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 01 Feb 2015 Phase-II clinical trials in Hepatitis B (Treatment-experienced) in New Zealand (PO) (NCT02391805)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top